<<You then have what is showing out to be over time a huge risk in regards to chronic glucocorticoid therapy.>>
Count me a sceptic of the 'huge risk associated' with such extreme intermittency. The only exception would be if some of the glucocorticoid side effects intersect with known TTR alyloidosis side effects.
See, for example, the below site which notes that the risk of such infrequent intermittency is pretty low in comparison to the known data for IONS technology and thrombo or renal. (And note the one issue with the IONS technology is that one of its known side effects intersects with a known TTR Issue - renal adverse events).
http://onlinelibrary.wiley.com/doi/10.1002/art.22294/full That said, this whole class of drugs (oligo) has surprises. So it won't surprise me much to see something bad pop up in the ALNY trial.